Medication burden, characterized by polypharmacy and suboptimal treatment adherence, is a predictor for acute care use among ...

At the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, Alexa Meara, MD, explored the interface of oncology and rheumatology in the immunotoxicity ...

Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary ...

A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...

Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...

A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...

In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...

The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, ...

A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung ...

Regarding efficacy, the phase 1 trial showed impressive objective response rates (ORR), approaching 70%. Typical PRRT alone ...

The FDA has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of adult patients with high-risk ...

Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...